source
- FDA Approves T-DXd for Early-Stage HER2+ Breast CancerThe FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.onclive · 3mo ago↗ source
- Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate CancerMark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.onclive · 3mo ago↗ source
- STAT+: FDA leadership shakeup widens following Makary’s departureThe acting director of the FDA’s drug center, Tracy Beth Høeg, is leaving the agency. The news come days after Commissioner Marty Makary handed in his resignation.STAT · 3mo ago